Immunome, Inc. (NASDAQ: IMNM), a biopharmaceutical company developing novel first-in-class antibody therapeutics targeting oncology and infectious diseases, announced the receipt of a clinical hold letter from the U.S. Food and Drug Administration (FDA) for its recently submitted Investigational New Drug (IND) for IMM-BCP-01, a three-antibody...
CytoKinetics, Inc. (NASDAQ: CYTK), a late-stage biopharmaceutical company, is developing therapeutics for the treatment of cardiovascular and neuromuscular diseases that are characterized by impaired muscle function such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA) heart failure and hypertrophic cardiomyopathies (HCM). The Company announced preclinical...
Novan, Inc. (NASDAQ: NOVN), a clinical–stage Biotechnology Company leveraging its expertise in nitric oxide-based therapies, has entered into a Master Services Agreement (MSA) with Catalent for supporting the development and chemistry, manufacturing and control (CMC) activities for berdazimer sodium, to be made into an intranasal...
Co-Diagnostics (NASDAQ: CODX), a molecular Diagnostics Company focused on developing nucleic acid molecule based reagents for diagnostic tests, announced the successful initial verification of its screening test, used for detecting the presence of the novel coronavirus. The polymerase chain reaction (PCR) screening test will soon...
According to the World Health Organization (WHO), Coronovirus (CoV) is a family of viruses that cause illnesses ranging from common cold to lethal diseases such as the Middle East Respiratory Syndrome (MERS-CoV), Severe Acute Respiratory Syndrome (SARS-CoV) and a new strain of CoV named, novel...
Inovio Pharmaceuticals (NASDAQ: INO), a late-stage biotechnology Company developing DNA-based immunotherapies and vaccines to combat cancer and infectious diseases, announced the grant of up to $9 million by the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine for Coronavirus 2019-nCoV, a deadly new...
